News

UK-based Pharmaceutical research firm C4X Discovery recently starting using Unreal Engine technology to visualize and manipulate 3-D molecules in virtual reality, with the potential to let scientists collaborate remotely in the virtual environment.

Early results point to novel approaches to drug discovery for this debilitating disease

Manchester and Oxford, UK, 6 December 2018: C4X Discovery Holdings plc (C4X.L) ("C4XD") and e-therapeutics plc (AIM: ETX, "e-therapeutics"), the network-driven drug discovery (NDD) company, are pleased to announce an update on their collaboration (announced 1st May 2018) to identify novel intervention strategies for the potential treatment of Parkinson’s Disease (PD).

Need to find innovative medicines fuels new collaborations for UK small-caps

...Take C4X, a drug discovery and development company that has a wholly-owned drug pipeline but is also developing molecules in partnership with pharma, biotech and academia.

Clive Dix, chief executive, says large pharmaceutical companies “are crying out for innovation and are struggling to get enough of it in their own organisation to have the best molecules coming through. They’re therefore going to . . . smaller, more innovative companies and licensing products from them”.

Its proprietary technologies include a tool that analyses genetic databases, and another that determines the 3D shape of drug molecules while they are still at the test-tube stage.

Partnership to maximise insights from shape-based chemistry and generate novel drug candidates in neurodegeneration

29 November 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that it has entered into a drug discovery partnership with GTN Ltd. (“GTN”), a disruptive new player in the field of drug discovery artificial intelligence (“AI”), initially focussing on identifying potential small molecule hits against a high-value neurodegeneration target.

“Manchester based C4X Discovery celebrated the only double win on the night, achieving the Bionow Project of the Year award for the development of Orexin-1 Receptor Antagonists for the Treatment of Addiction, while its Lead Software Developer Phil Muwanga won in the prestigious Promising Technologist of the Year category. Phil is applying gaming technology and virtual reality to revolutionise the drug discovery industry allowing scientists to visualise how drugs interact with our bodies at the molecular level…"

27 November 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that it has entered into a discovery partnership with LifeArc®, one of the UK’s leading medical research charities. C4XD and LifeArc will join forces to progress medicinal chemistry efforts on a novel, commercially attractive programme with applicability across oncology and inflammation indications. The undisclosed target originated from LifeArc’s extensive partnerships in early-stage academic research.

21 November 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its full year results for the year ended 31 July 2018.

Taking a patient-centered approach, Indivior is developing innovative treatments for addiction to opioids, alcohol, and stimulants, as well as accompanying illnesses such as schizophrenia.

...selective blockade of the OX1 receptor decreases drug seeking and prevents relapse or reinstatement of drug-seeking behavior during abstinence in animal models of addiction. Indivior has entered into a partnership with C4X Discovery to develop their lead molecule, C4X3256, a selective OX1 receptor antagonist.